Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Lotilaner · Xdemvy

Small molecule · Inhibitor · developed by Tarsus

Approved FDA, Jul 2023
TARS Developer
1 Registered trials

What is Lotilaner?

Lotilaner is a small molecule that inhibits gamma-aminobutyric acid (GABA)-gated chloride channels in mites, causing paralysis and death of the parasite. It is an ectoparasiticide studied in ocular rosacea.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Xdemvy
Drug type
Small molecule
Mechanism
Inhibitor
Pathways
GABA-gated chloride channel inhibition
Therapy area
Dermatology
Developer
Tarsus (TARS)
FDA status
Approved as Xdemvy (July 24, 2023), NDA217603 · FDA label
UNII
HEH4938D7K

✅ FDA-approved uses

From the indications section of the FDA label (version of Aug 10, 2024). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07443202 Phase 2 Ocular Rosacea Enrolling by invitation TARS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Ocular Rosacea

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the TARS page.

Follow TARS, the company behind Lotilaner

See TARS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TARS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.